Skip to main content

Table 1 Demographic and baseline data for the mild cognitive impairment group

From: For debate: substituting placebo controls in long-term Alzheimer's prevention trials

Characteristic Value
  (n = 397)
Age (years) 74.2 (7.4)
Women 141 (36%)
Apolipoprotein E4  
   0 E4 alleles 185 (47%)
   1 E4 allele 165 (42%)
   2 E4 alleles 47 (12%)
Education (years) 15. 7 (3.0)
Body mass index (kg/m2) 26.1 (4.0)
Hachinski modified (0 to 12) 1 (0 to 4)
FAQ (0 (normal) to 50) 2 (0 to 21)
MMSE (0 to 30 (best)) 27.0 (1.8)
ADAScog, modified (0 (best) to 85) 18.6 (6.3)
NP-Batt (z score) -1.02 (0.66)
Medication 240 (60%)
  (n = 199)
β-amyloid1-42 146.9 (48.3 to 298.8)
Total tau protein 85.6 (28.5 to 463.2)
β-amyloid1-42/total tau protein 1.564 (0.233 to 7.61)
  1. Data presented as mean (standard deviation), n (%) or median (minimum to maximum). ADAScog, Alzheimer Disease Assessment Scale - cognitive subscale; FAQ, Functional Assessment Questionnaire; MMSE, Mini-Mental State Examination; NP-Batt, Neuro-Psychological Battery.